69 F
Pakistan
Saturday, March 28, 2026
HomeHealthBiomednewsbreaks - Soligenix Inc. (NASDAQ: SNGX) Receives EU Orphan Drug Designation For...

Biomednewsbreaks – Soligenix Inc. (NASDAQ: SNGX) Receives EU Orphan Drug Designation For Dusquetide In Behçet Disease

(MENAFN – Investor Brand Network) Soligenix (NASDAQ: SNGX) announced the European Commission has granted orphan drug designation to dusquetide (SGX945) for the treatment of Behc–et Disease, .. .

Read full story on Menafn

RELATED ARTICLES

LEAVE A REPLY

Please enter your comment!
Please enter your name here

- Advertisment -
Google search engine

Most Popular

Recent Comments